Maxim Group reaffirmed their buy rating on shares of bluebird bio, Inc. (NASDAQ:BLUE) in a report published on Monday morning, MarketBeat reports. Maxim Group currently has a $170.00 price target on the biotechnology company’s stock, up from their prior price target of $100.00.
Other research analysts have also issued reports about the stock. Jefferies Group LLC reissued a buy rating on shares of bluebird bio in a research note on Thursday, July 6th. Zacks Investment Research raised shares of bluebird bio from a hold rating to a buy rating and set a $118.00 price objective on the stock in a research note on Tuesday, July 4th. BidaskClub lowered shares of bluebird bio from a strong-buy rating to a buy rating in a research note on Friday, June 30th. Cowen and Company reaffirmed a buy rating on shares of bluebird bio in a research note on Friday, June 23rd. Finally, BTIG Research reaffirmed a buy rating and issued a $112.00 price objective on shares of bluebird bio in a research note on Wednesday, June 28th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus price target of $118.81.
bluebird bio (NASDAQ BLUE) opened at 130.20 on Monday. The company’s market capitalization is $5.94 billion. bluebird bio has a 12 month low of $37.05 and a 12 month high of $143.50. The stock’s 50 day moving average is $125.54 and its 200-day moving average is $101.98.
bluebird bio (NASDAQ:BLUE) last issued its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.66) by ($0.07). The company had revenue of $16.70 million for the quarter, compared to the consensus estimate of $6.29 million. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The firm’s revenue was up 977.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.59) earnings per share. On average, analysts expect that bluebird bio will post ($6.79) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “bluebird bio, Inc. (BLUE) Stock Rating Reaffirmed by Maxim Group” was first published by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/2956608/bluebird-bio-inc-blue-stock-rating-reaffirmed-by-maxim-group.html.
In related news, insider Jeffrey T. Walsh sold 4,900 shares of the firm’s stock in a transaction dated Tuesday, October 10th. The shares were sold at an average price of $129.94, for a total transaction of $636,706.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Nick Leschly sold 46,833 shares of the firm’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $122.27, for a total transaction of $5,726,270.91. Following the sale, the insider now owns 289,368 shares of the company’s stock, valued at approximately $35,381,025.36. The disclosure for this sale can be found here. Insiders have sold 131,779 shares of company stock worth $16,038,514 over the last three months. 3.90% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. QS Investors LLC increased its holdings in bluebird bio by 70.7% during the second quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after buying an additional 500 shares during the last quarter. Bank of Montreal Can increased its holdings in bluebird bio by 118.9% during the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock worth $176,000 after buying an additional 911 shares during the last quarter. Turner Investments LLC purchased a new stake in bluebird bio during the second quarter worth about $184,000. SG Americas Securities LLC increased its holdings in bluebird bio by 17.9% during the second quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock worth $204,000 after buying an additional 295 shares during the last quarter. Finally, Fairfield Bush & CO. purchased a new stake in bluebird bio during the second quarter worth about $210,000.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.